Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Gilead Sciences, Inc.U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex RegimensCompanies: Gilead SciencesFOSTER CITY, Calif., August 27, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed.
- Kane Biotech Announces Second Quarter 2026 Financial ResultsKane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
- City of Irvine and SpyGlass PharmaSpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D SpaceFuture portfolio expansion will advance a new era of ophthalmic care while driving continued growth of Irvine's MedTech and life sciences sector. — SpyGlass Pharma, a biopharmaceutical clinical-stage company dedicated to transforming treatment...
- Pomerantz LLPINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hims & Hers Health, Inc. - HIMSPomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
- Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerPfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.1
- Pfizer Inc.Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineCompanies: PfizerNEW YORK & MAINZ, Germany, August 27, 2026--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying cond
- IQVIAIQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and HealthcareCompanies: IQVIA Holdings, Inc.RESEARCH TRIANGLE PARK, N.C., August 27, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced it received recognition this year from multiple independent industry awards programs for its use of AI to help healthcare and life sciences organizations improve decisions, strengthen regulated workflows, protect patient privacy and optimize clinical trial execution
- Water Tower Research Publishes Initiation of Coverage Report on PharmAla Biotech Holdings, Inc., “Monetizing Regulatory Advantage Through IP and Data”August 27, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on PharmAla Biotech Holdings, Inc. (CSE:MDMA/OTC:MDXXF) titled, “Monetizing Regulatory Advantage Through IP and Data”. The report can be accessed here. PharmAla Biotech […]
- FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in CattleThe U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound – advancing the Trump Administration's goal of safeguarding American agriculture from NWS. Bimectin injection is not authorized for use in lactating dairy cows or in calves that will be processed for veal.
- Jersey CollegeJersey College York Campus Marks First Graduation and a New Generation of Nurses in PennsylvaniaInaugural graduating class demonstrates how Jersey College's hospital partnership with WellSpan Health creates a pathway from nursing education to the regional workforce
- Sports ResearchSports Research® Expands Creatine Portfolio as the Category Evolves Beyond Traditional Sports Performance into Everyday WellnessNew Creatine Capsules launch at Costco and Amazon, delivering 5 grams of creatine monohydrate per serving in a convenient capsule format. — Sports Research®, a leading health and wellness company, today announced the launch of its new Creatine...
- Incuvio Health LLCIncuvio Health Expands Business Process Outsourcing (BPO) Capabilities to Help Healthcare Organizations Scale with ConfidenceExpanded BPO services strengthen Incuvio Health's ability to support healthcare organizations through technology-enabled operational excellence, clinical expertise, and scalable workforce solutions. — Incuvio Health today announced the expansion of...